Document Detail

Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies.
MedLine Citation:
PMID:  23321403     Owner:  NLM     Status:  MEDLINE    
The purpose of this study was to evaluate a fixed olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and some inflammatory markers compared with single-drug monotherapy. A total of 276 hypertensive patients were randomly assigned to olmesartan 20 mg, amlodipine 10 mg, or a single pill containing olmesartan/amlodipine combination 20/5 mg for 12 months. We evaluated the following at baseline and after 6 and 12 months: body weight, body mass index, systolic (SBP) and diastolic blood pressures (DBP), fasting plasma glucose (FPG), fasting plasma insulin (FPI), lipid profile, tumor necrosis factor-α (TNF-α), retinol binding protein-4 (RBP-4), and interleukins 6 and 7 (IL-6 and IL-7). At baseline, and after 6 and 12 months, patients underwent an euglycemic, hyperinsulinemic clamp. The olmesartan/amlodipine combination provided a greater decrease of SBP and DPB compared with amlodipine and olmesartan monotherapies. The olmesartan/amlodipine combination decreased FPG after 12 months compared with amlodipine monotherapy. The combination decreased FPI and homeostasis model assessment index and increased M value both compared with baseline and with olmesartan and amlodipine monotherapies. Olmesartan/amlodipine decreased IL-7, but not IL-6, compared with single drug components. The olmesartan/amlodipine combination is effective and safe in reducing blood pressure and has some additive effects not shown by single drugs, such as an improvement of IL-7.
Giuseppe Derosa; Arrigo F G Cicero; Anna Carbone; Fabrizio Querci; Elena Fogari; Angela D'Angelo; Pamela Maffioli
Related Documents :
2394653 - Nature of pulmonary hypertension in canine oleic acid pulmonary edema.
24431783 - Pressure produced on the residual maxillary alveolar ridge by different impression mate...
591103 - Increase in the severity of allergic-type bronchospasm in sensitized and challenged cat...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of the American Society of Hypertension : JASH     Volume:  7     ISSN:  1878-7436     ISO Abbreviation:  J Am Soc Hypertens     Publication Date:    2013 Jan-Feb
Date Detail:
Created Date:  2013-01-16     Completed Date:  2013-07-09     Revised Date:  2013-09-23    
Medline Journal Info:
Nlm Unique ID:  101312518     Medline TA:  J Am Soc Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  32-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.
Department of Internal Medicine and Therapeutics, University of Pavia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amlodipine / administration & dosage*
Angiotensin II Type 1 Receptor Blockers / administration & dosage
Antihypertensive Agents / administration & dosage
Biological Markers / blood
Blood Pressure / drug effects
Drug Combinations
Hypertension / drug therapy*,  immunology*,  metabolism
Imidazoles / administration & dosage*
Interleukin-6 / blood
Interleukin-7 / blood
Tetrazoles / administration & dosage*
Treatment Outcome
Tumor Necrosis Factor-alpha / blood
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Biological Markers; 0/Drug Combinations; 0/IL6 protein, human; 0/IL7 protein, human; 0/Imidazoles; 0/Interleukin-6; 0/Interleukin-7; 0/Tetrazoles; 0/Tumor Necrosis Factor-alpha; 88150-42-9/Amlodipine; 8W1IQP3U10/olmesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-term follow-up of patients with atherosclerotic renal artery disease.
Next Document:  Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patient...